21-12-2017
Hailshadow / iStockphoto.com
Médecins Sans Frontières (MSF) has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Médecins Sans Frontières, MSF, Gilead, hepatitis C, I-MAK, Sovaldi, sofosbuvir, SIPO, State Intellectual Property Office
MSF urges EU to rid market of ‘avoidable suffering’ from SPCs
30-11-2020
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17-09-2018
MSF challenges Gilead patent in China
20-06-2018
Non-profit asks US government to take Gilead hepatitis C patent
20-03-2018
Gilead gets Sovaldi patent approval in India despite opposition
10-05-2016
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
02-03-2016
